Group items matching

in title, tags, annotations or url

The American Diabetes Association is accepting applications for its Innovative Basic Science Awards. Through the annual research program, the association awards grants of up to $115,000 over three years in support of creative and innovative projects that hold significant promise for advancing the prevention, cure, or treatment of Diabetes. Priority is given to high-risk projects with the potential to generate high-impact results; projects that extend existing knowledge into a new area or application; projects that utilize novel technological or cross-disciplinary approaches; and/or projects that may not be sufficiently developed for traditional funding sources (e.g., NIH R01). Applicant must hold a PhD, MD, PharmD, DO, or DPM degree (or, for other health professionals, the equivalent doctoral-level health- or science-related degree) and possess the necessary skills and training to carry out the proposed work. At the time of application, applicants must hold a full-time independent faculty position or the equivalent at a university-affiliated research institution or other nonprofit research institution. (Awards are limited to institutions in the United States and U.S. possessions.) See the ADA website for complete program guidelines and application instructions.

This Funding Opportunity Announcement (FOA) encourages NIH Research Project Grants (R01) to test practical, sustainable, and cost efficient adaptations of efficacious strategies or approaches to prevent and treat diabetes and/or obesity. Research focused on the prevention or reversal of obesity, prevention of type 2 diabetes, improved care of type 1 and type 2 diabetes, or the prevention or delay of the complications of these conditions is encouraged. The approaches tested should have the potential for wide dissemination and implementation outside of an academic setting such as in routine clinical practice or communities at risk.

The goal of this FOA is to encourage applications from institutions/organizations proposing to develop, refine, and pilot test innovative strategies to improve diabetes management in pre-teens (ages 10-12), adolescents (ages 13-18) and/or young adults (ages 19-30) with type 1 diabetes. 

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).

to request research applications that test innovative approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care?. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve healthcare practice and inform healthcare policy for the prevention or management of these conditions

To that end, the association invites applications for its Junior Faculty Development (JFD) and Minority Junior Faculty Development (JDFM) Awards Through the JDF program, grants of $138,000 per year plus optional student loan repayment ($10,000 per year) will be awarded over two to four years to help early investigators establish their independence in diabetes research. Through its JDFM program, grants of $138,000 per year plus optional student loan repayment ($10,000 per year) will be awarded over two to four years to minority early investigators to help them establish their independence in diabetes research.

This Limited Competition Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the six current Clinical Centers (CCs) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study of Type 1 Diabetes (T1D) etiology. The TEDDY study involves the rigorous investigation of TEDDY subjects, collecting data and samples, for the identification of infectious agents, dietary factors, or other environmental factors associated with onset of T1D and/or T1D associated autoimmune markers. The six current CCs have been involved in study design and data and biosample acquisition since the inception of the TEDDY consortium. The CCs have recruited participants and followed the subjects over the past 15 years. In addition, the CCs have established effective and proficient collaborations with other components of TEDDY to carry out the studies to meet the objectives of this program.

This Funding Opportunity Announcement (FOA) invites applications for studies on the complications of type 1 diabetes using subjects and/or samples from clinical studies on type 1 diabetes.

This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.

This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.

All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in Diabetes Research Center topic areas. 

This Funding Opportunity Announcement (FOA) invites applications for studies on the complications of type 1 diabetes using subjects and/or samples from clinical studies on type 1 diabetes.

This Limited Competition Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the six current Clinical Centers (CCs) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study of Type 1 Diabetes (T1D) etiology. The TEDDY study involves the rigorous investigation of TEDDY subjects, collecting data and samples, for the identification of infectious agents, dietary factors, or other environmental factors associated with onset of T1D and/or T1D associated autoimmune markers. The six current CCs have been involved in study design and data and biosample acquisition since the inception of the TEDDY consortium. The CCs have recruited participants and followed the subjects over the past 15 years. In addition, the CCs have established effective and proficient collaborations with other components of TEDDY to carry out the studies to meet the objectives of this program. This FOA will support the CCs to allow them to continue to retain, follow clinically, and collect biosamples and data from TEDDY subjects.

The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering andtransformational studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

Through this annual research program, the association awards grants of up to $115,000 over three years in support of innovative projects that hold significant promise for advancing the prevention, cure, or treatment of diabetes. Priority is given to high-risk projects with the potential to generate high-impact results; that extend existing knowledge into a new area or application and that utilize novel technological or cross-disciplinary approaches; and/or that may not be sufficiently developed for traditional funding sources

The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research must reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research must reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.

The purpose of this Funding Opportunity Announcement is to invite applications that investigate the mechanisms mediating the interactions between sleep and diabetes-related metabolism using deep metabolic phenotyping approaches in healthy human populations and those with metabolic and/or sleep disorders.

The purpose of this Funding Opportunity Announcement is to invite applications that investigate the mechanisms mediating the interactions between sleep and diabetes-related metabolism using deep metabolic phenotyping approaches in healthy human populations and those with metabolic and/or sleep disorders.